February 23, 2016
John Michael McWilliams, MD, PhD
Associate Professor of Health Care Policy, Harvard Medical School
Practicing general internist, Brigham & Women’s Hospital
April 20, 2016
David Auerbach, PhD, MS
Deputy Director for Research and Cost Trends, Massachusetts Health Policy Commission
May 11, 2016
Stéphane Verguet, PhD, MPP, MS
Assistant Professor of Global Health, Department of Global Health and Population, Harvard
School of Public Health
September 27, 2016
Scott Ramsey, Md, PhD
Director, Hutchinson Institute for Cancer Outcomes Research
October 5, 2016
Umbereen Nehal, MPH, PhD
Associate Medical Director of MassHealth
November 9, 2016
Mehdi Najafzadeh, PhD
Instructor of Medicine, Division of Pharmacoepidemiology & Pharmacoeconomics,
Brigham & Women's Hospital, Harvard Medical School
December 21, 2016
Adam Rose, MSc, MD
Physican Policy Researcher, RAND Corporation
June 2, 2015
On June 2nd Cayla Saret and Peter Neumann discussed their recent paper When does FDAMA 114 apply? 10 case studies and its implications.
If you would like to attend future webinars, pleas contact Julie Lannon at firstname.lastname@example.org.
December 3, 2014
On December 3, 2014, Peter Neumann and James Chambers hosted a webinar for CEVR sponsors where they discussed the implications of our recent study "Do specialty drugs offer value for money? Highlights from our new Health Affairs paper.
September 10, 2014
The Center for the Evaluation of Value and Risk in Health hosted a symposium on Innovation and Cost-Effectiveness Analysis followed by a dinner to celebrate the 15th Anniversary of the CEA Registry, on September 10th at the Four Seasons in Washington DC. For photo highlights from the event visit our blog here.
February 6, 2013
The Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center invites you and your colleagues to participate in a discussion on the economics of mild cognitive impairment (MCI) and the importance of further research into the potential cost-effectiveness of early diagnosis.